INAB
NASD IN8bio, Inc.$1.29 ↓ -0.00 (-0.39%) Trading Down from the previous close of $1.30, $0.01 below the day’s high of $1.30
- YTD change
- -44.87%
- vs 20-day SMA
- +15.75%
- vs 200-day SMA
- -16.80%
Price ranges
Price & Performance
-0.08 (-5.47%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.6% away from all-time highs of $309.57
- INAB is down 45% since the beginning of the year
- INAB is down 43% over the past 12 months
- INAB is up 25% over the past 1 month
- 1% of all INAB investors are betting against INAB
INAB reads very good: price sits above one of the two key moving averages, the 12-month move is -42.7%.
- Previous minute
- +$0.00
- Last hour
- -$0.01
- Last 5 days
- +21.70%
- vs 8-day SMA
- +13.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Competitor comparison
No peer group available for this symbol.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.